SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 5 analyzed stories

Nurix Therapeutics Says Sanofi Will End SAR448272 Program

Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminate the program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties for SAR448272.

Published:

Updated:

What happened

Sanofi told Nurix Therapeutics it will end an early-stage trial and stop developing SAR448272, an experimental oral drug studied for inflammatory and autoimmune conditions. Nurix said it no longer expects milestone payments or royalties from this drug. Other drug candidates in its Sanofi collaboration remain eligible for payments.

Global impact / market context

The decision removes expected future payments tied to SAR448272, which could weigh on Nurix. The supplied facts do not say how the market reacted or whether other parts of the collaboration have changed.

What to watch

  1. Check whether Nurix gives any further update on the SAR448272 program, because the company says it no longer expects payments tied to it.
  2. Check whether Sanofi continues developing the other drug candidates in its collaboration with Nurix, because those candidates remain eligible for payments.
  3. Check for updates on the early-stage trial ending and program termination, because these confirm the status of the discontinued drug.

Affected assets

  • Nurix Therapeutics, Inc.
  • Sanofi

Evidence